Quince Therapeutics Announces 1-for-10 Reverse Stock Split

Quince Therapeutics ( (QNCX) ) has shared an update.

Quince Therapeutics, Inc. will implement a 1-for-10 reverse stock split of its common stock, approved by stockholders on June 4, 2025 and authorized by the board, with the related certificate of amendment filed in Delaware on April 9, 2026 and becoming effective at 11:59 p.m. Eastern Time on April 10, 2026. The shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on April 13, 2026, reducing the outstanding share count to about 16.3 million, leaving ownership percentages and rights unchanged except for cash in lieu of fractional shares, and triggering proportional adjustments to all outstanding stock options and warrants.

Following the reverse stock split, Quince’s common stock will continue to trade under the ticker QNCX but under a new CUSIP number, while its transfer agent Equiniti Trust Company, LLC will act as exchange agent to manage the corporate action. The move is designed to consolidate the company’s capital structure without diluting existing investors, and positions the stock for trading at a higher per-share price while minimizing operational burden on shareholders, whose positions held through brokers will be adjusted automatically.

The most recent analyst rating on (QNCX) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.

Spark’s Take on QNCX Stock

According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.

The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on QNCX stock, click here.

More about Quince Therapeutics

Quince Therapeutics, Inc. is a biotechnology company whose common stock trades on the Nasdaq Global Select Market under the symbol QNCX. The company operates within the life sciences sector, with its shareholder base primarily composed of investors in publicly listed biopharmaceutical and therapeutic development companies.

Average Trading Volume: 99,127,025

Technical Sentiment Signal: Sell

Current Market Cap: $10.2M

Find detailed analytics on QNCX stock on TipRanks’ Stock Analysis page.